Advancing Thyroid Nodule Molecular Science
Afirma® 2025
Research Collection:
Thyroid Insights & Data
A comprehensive compilation of novel research demonstrating Afirma’s whole-transcriptome capabilities in advancing thyroid nodule diagnostics.
A Comprehensive Review of Afirma’s Novel Research Presented in 2025
Through whole-transcriptome analysis of every thyroid nodule we receive, Veracyte has built one of the most comprehensive genomic databases in thyroid nodule diagnostics.
This powerful approach not only serves as the foundation for Afirma GSC, but also creates the potential for novel research that advances our understanding of thyroid tumors like the molecular diagnostic studies featured in this collection.
"*" indicates required fields
Featured Studies
This document is a collection of research using Afirma GSC presented in collaboration with Veracyte in 2025, with succinct summaries and explanations of each. Additional information on 5 independent abstracts that utilized Afirma data is also included.
The Expression of Cell-Surface Targets as Potential Prognostic and Therapeutic Markers in Thyroid Tumors
An interrogation of 78 cell surface targets (CSTs) across Bethesda III – VI thyroid nodules sent for Afirma GSC testing that uncovered potential novel therapeutic targets for thyroid carcinomas.
Single-cell RNA sequencing analysis of thyroid nodule fine needle biopsy aspiration
An exploration of the feasibility of single-cell RNA sequencing, which could be used to identify cell subpopulations in the tumor microenvironment and may provide unique genomic insights.
The Genomic Landscape of 250,000+ Thyroid Nodules Undergoing Exome- Enriched RNA Sequencing
A study investigating the molecular findings across a large, real-world cohort of over 252,510 Bethesda III – VI thyroid nodules fine needle aspiration biopsies sent for Afirma GSC testing.
2025 represented a significant leap forward with a greater number of abstracts presented, several independent studies, and multiple abstracts that received awards throughout the year. In addition, these studies aren’t limited to being diagnostic or prognostic in nature; with studies pursuing potential therapeutic targets for advanced thyroid cancer included as well.”
Medical Director,
Endocrinology
Explore Research Opportunities with Afirma
If you have any questions about the studies presented in this document or would like to discuss ideas for your own research, request a meeting with our friendly Afirma Medical Science Liaison (MSL) team.